Masitinib, a tyrosine kinase inhibitor targeting mast cells and macrophages, showed significant effects on both cognition and daily activity as adjunctive treatment in a phase IIb/III study of mild to moderate Alzheimer's patients, drug maker AB Science said.

The protein YKL-40 linked Alzheimer's disease to circadian rhythm dysfunction, suggesting it could be targeted to reduce Alzheimer's progression. (Science Translational Medicine)

A case series looked at ICU patients with severe COVID-19 who remained in prolonged comatose states after sedatives were stopped. (Neurology)

The S1 protein of SARS-CoV-2 readily crossed the bloodbrain barrier in male mice. (Nature Neuroscience)

Masks change the way people perceive faces. (Scientific Reports)

Johns Hopkins researchers issued a report to help federal, state, and local policymakers reduce opioid overdose deaths during the COVID-19 pandemic.

Brain volume may affect the effectiveness of deep brain stimulation in Parkinson's disease patients. (Scientific Reports)

A chartbased delirium detection tool improved diagnostic accuracy when used with routine delirium screening tools. (Journal of the American Geriatrics Society)

Sleeponset latency predicted 7year cognitive change in middle-age to older Hispanic/Latino adults. (Alzheimer's & Dementia)

Researchers took aim at the National Football League for using race norms to adjust cognitive scores of retired Black NFL players, thus denying them compensation for dementia-related settlement claims. (JAMA Neurology)

The "patience, love, and devotion" of Alzheimer's care, documented by a photographer in Iran. (STAT)

Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimers, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinsons, ALS, concussion, CTE, sleep, pain, and more. Follow

Read the rest here:
Positive Alzheimer's Data; Comatose With COVID; Race, Dementia, and the NFL - MedPage Today